All participants were smokers or had either diabetes, cancer, depression, cardiovascular, respiratory, thyroid, or gastrointestinal disease and were receiving a DMT.
Natural history data from a subset of patients from the British Columbia MS database between 1980 to 1996 were used to create a continuous Markov model to model the projected course of disease in untreated people with RMS.
Researchers categorized samples into quintiles based on 25(OH)D3 concentrations in healthy controls.
Patients with progressive MS or secondary progressive MS who were receiving care at a single institution in France were prescribed 300 mg/day MD1003.
Disability progression is slower among patients with pediatric-onset multiple sclerosis.
In patients with relapse-remitting multiple sclerosis, the initiation of oral disease-modifying therapies is associated with a lower relapse risk as well as a lower risk for disability progression.
Investigators examine the effect of disease-modifying therapy on the rate of brain atrophy in patients with multiple sclerosis.
Patients with MS also have a higher risk for serious hospitalized-related infections compared with hospitalized patients without MS.
Study investigators assessed the changes in the Expanded Disability Status Scale and MS Severity Score after up to 7 courses of alemtuzumab.
The phase 3 PARADIGMS trial involving 215 pediatric patients demonstrated superior efficacy for fingolimod over interferon beta-1a.
Patients were divided into 3 groups: patients not treated in the 3 months before pregnancy, patients treated in the 3 months before pregnancy, and patients treated during pregnancy.
Treatments were evaluated for either 1 year (SUNBEAM) or 2 years (RADIANCE).
Participants showed a significant decrease in annual relapse rate and a significant improvement in both patient-reported disability scores and information processing scores.
Researchers pooled long-term data on the safety of cladribine tablets monotherapy that extended 3 or more years beyond the data included in the last clinical study.
Surveys were given out to individuals in the Australian Multiple Sclerosis Longitudinal Study between August and December 2016.
Evidence suggests a possible role for inflammation in the association between MS and myocardial infarction risk.
Reserachers evaluated data from the CLARITY study to test the efficacy of cladribine tablets on frequency and severity of relapses for patients with multiple sclerosis.
Patients with multiple sclerosis who initiated ocrelizumab therapy earlier and continued long-term treatment sustained lower annualized relapse rates.
Researchers analyze the dietary habits of 260 patients in the early stages of multiple sclerosis from baseline to 5 years after initial onset of symptoms.
Early initiation of dimethyl fumarate and fingolimod may be associated with improved relapse control in multiple sclerosis relative to late therapy initiation.
Extended interval dosing of natalizumab may also be associated with reduced risk for progressive multifocal leukoencephalopathy.
The ESTEEM study included 3075 patients who were newly prescribed dimethyl fumarate to manage relapsing-remitting multiple sclerosis.
Previous studies have shown that excess adiposity is a strong risk factor for metabolic comorbidities and has been linked to poorer outcomes in people with neurologic diseases.
Multiple sclerosis disease activity was less likely to decrease among tobacco users.
Neurology Advisor Articles
- Vitamin D3 Associated With Reductions in Migraine Days Among Migraineurs
- Hemicrania Continua: Diagnosis and Treatment
- Psychiatric Adverse Effects from Levetiracetam Linked to Certain Factors
- Predicting Outcomes in Parkinson Disease: Utility of EEG
- Prolonged Aura in Migraine Linked to More Sensory Symptoms
- Overlapping Phenomenology in Focal Motor Epilepsy and Movement Disorders
- Walgreens Now Offers Next-Day Prescription Medication Delivery With FedEx
- MFIQ Comprehensively Evaluates Migraine Intervention Outcomes
- Lorcaserin May Reduce Motor Seizures in Pediatric Treatment-Resistant Epilepsy
- Guidance for Antibiotic Use in Myasthenia Gravis